128 related articles for article (PubMed ID: 36965174)
1. Combined treatment with venetoclax, dasatinib, and FLT3 inhibitors for NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia: A pediatric case report.
Wen X; Wu Y; Huang P; Zheng H
Pediatr Blood Cancer; 2023 Jul; 70(7):e30308. PubMed ID: 36965174
[No Abstract] [Full Text] [Related]
2. Dasatinib and navitoclax act synergistically to target NUP98-NSD1
Kivioja JL; Thanasopoulou A; Kumar A; Kontro M; Yadav B; Majumder MM; Javarappa KK; Eldfors S; Schwaller J; Porkka K; Heckman CA
Leukemia; 2019 Jun; 33(6):1360-1372. PubMed ID: 30568173
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
Mitani Y; Hiwatari M; Seki M; Hangai M; Takita J
Int J Hematol; 2019 Oct; 110(4):512-516. PubMed ID: 31134509
[TBL] [Abstract][Full Text] [Related]
4. Pediatric acute myeloid leukemia co-expressing FLT3/ITD and NUP98/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: A case report.
Abematsu T; Nishikawa T; Shiba N; Iijima-Yamashita Y; Inaba Y; Takahashi Y; Nakagawa S; Kodama Y; Okamoto Y; Kawano Y
Pediatr Blood Cancer; 2021 Nov; 68(11):e29216. PubMed ID: 34245496
[No Abstract] [Full Text] [Related]
5. Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
Miyajima T; Onozawa M; Yoshida S; Miyashita N; Kimura H; Takahashi S; Yokoyama S; Matsukawa T; Goto H; Sugita J; Fujisawa S; Hidaka D; Ogasawara R; Mori A; Matsuoka S; Shigematsu A; Wakasa K; Kasahara I; Saga T; Hashiguchi J; Takeda Y; Ibata M; Yutaka T; Fujimoto K; Kondo T; Teshima T
Eur J Haematol; 2023 Oct; 111(4):620-627. PubMed ID: 37465857
[TBL] [Abstract][Full Text] [Related]
6. NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR.
Akiki S; Dyer SA; Grimwade D; Ivey A; Abou-Zeid N; Borrow J; Jeffries S; Caddick J; Newell H; Begum S; Tawana K; Mason J; Velangi M; Griffiths M
Genes Chromosomes Cancer; 2013 Nov; 52(11):1053-64. PubMed ID: 23999921
[TBL] [Abstract][Full Text] [Related]
7. Potent co-operation between the NUP98-NSD1 fusion and the FLT3-ITD mutation in acute myeloid leukemia induction.
Thanasopoulou A; Tzankov A; Schwaller J
Haematologica; 2014 Sep; 99(9):1465-71. PubMed ID: 24951466
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT.
Sun H; Yan H; Yan Z; Zhu Y; Yang G; Zhang S
Ann Hematol; 2023 Feb; 102(2):473-475. PubMed ID: 36434435
[No Abstract] [Full Text] [Related]
9. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
10. High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
Shiba N; Ohki K; Kobayashi T; Hara Y; Yamato G; Tanoshima R; Ichikawa H; Tomizawa D; Park MJ; Shimada A; Sotomatsu M; Arakawa H; Horibe K; Adachi S; Taga T; Tawa A; Hayashi Y
Br J Haematol; 2016 Feb; 172(4):581-91. PubMed ID: 26684393
[TBL] [Abstract][Full Text] [Related]
11. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
Ostronoff F; Othus M; Gerbing RB; Loken MR; Raimondi SC; Hirsch BA; Lange BJ; Petersdorf S; Radich J; Appelbaum FR; Gamis AS; Alonzo TA; Meshinchi S
Blood; 2014 Oct; 124(15):2400-7. PubMed ID: 25145343
[TBL] [Abstract][Full Text] [Related]
12. NUP98::Nsd1 and FLT3-ITD collaborate to generate acute myeloid leukemia.
Matsukawa T; Yin M; Nigam N; Negi V; Li L; Small D; Zhu YJ; Walker RL; Meltzer PS; Aplan PD
Leukemia; 2023 Jul; 37(7):1545-1548. PubMed ID: 37147424
[No Abstract] [Full Text] [Related]
13. [Molecular Characteristics and Clinical Features of Adults with
Lun Y; Huang JC; Long D; Wang FF; Dai Y; Yang Y; Zhao TT; Li Q; Wu Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):575-581. PubMed ID: 30378313
[TBL] [Abstract][Full Text] [Related]
14. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
Greenblatt S; Li L; Slape C; Nguyen B; Novak R; Duffield A; Huso D; Desiderio S; Borowitz MJ; Aplan P; Small D
Blood; 2012 Mar; 119(12):2883-94. PubMed ID: 22323452
[TBL] [Abstract][Full Text] [Related]
15. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM
Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447
[TBL] [Abstract][Full Text] [Related]
16. Refractory pediatric acute myeloid leukemia expressing NUP98-NSD1 fusion gene responsive to chemotherapy combined with venetoclax and decitabine.
Xu H; Yu H; Xu J; Zhou F; Tang S; Feng X; Luo Q; Zhang B; Wu X; Jin R; Chen H
Pediatr Blood Cancer; 2023 Mar; 70(3):e30021. PubMed ID: 36184746
[No Abstract] [Full Text] [Related]
17. Acute myeloid leukemia with NUP98-HOXC13 fusion and FLT3 internal tandem duplication mutation: case report and literature review.
Tosić N; Stojiljković M; Colović N; Colović M; Pavlović S
Cancer Genet Cytogenet; 2009 Sep; 193(2):98-103. PubMed ID: 19665070
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
[TBL] [Abstract][Full Text] [Related]
19. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
[TBL] [Abstract][Full Text] [Related]
20. Concealed dagger in FLT3/ITD+ AML.
Ofran Y
Blood; 2014 Oct; 124(15):2317-9. PubMed ID: 25301331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
